Repurposing Drugs for Effective Treatment of Tuberculosis: A Promising Approach

Mycobacterium tuberculosis (M. tb), the pathogen responsible for tuberculosis (TB), remains a major global health threat, causing millions of deaths among active TB cases each year. The current treatment regimen, which is lengthy and complex, coupled with the rise of drug-resistant strains, highlights the urgent need for new therapeutic solutions. In response, drug repurposing has gained attention as a promising strategy against M. tb. This method involves finding new uses for existing medications, providing a faster and more cost-effective route to developing TB treatments than traditional drug discovery. By leveraging the known safety, pharmacological profiles, and side effects of approved drugs, drug repurposing offers a streamlined alternative in the search for effective TB therapies. This strategy has already yielded success with several non-TB drugs, such as linezolid, gatifloxacin, levofloxacin, moxifloxacin, meropenem, and clofazimine, which are effective in treating drug-resistant TB and are incorporated into treatment regimens. The advantages of drug repurposing, including cost savings, reduced development timelines, and the potential to address the challenges posed by drug-resistant TB, make it a valuable tool in the global fight against this formidable disease. The continued research into repurposed drugs holds the potential for developing more effective, accessible, and affordable TB treatments, moving us closer to achieving the End-TB 2035 goal.